semaglutide injection 0.5 mg Extensior mg/0.37 ml An Ongoing Crisis: Semaglutide Shortage

When researchers report that 40% of weight lost came from lean mass, they are not talking exclusively about skeletal muscle

Untreated Controls Preclinical injury models % reduction in healing time Tendon Transection (Rat Achilles model)50% Skin Wound Closure (Alkali burn model)45% Muscle Crush Injury (Rat quadriceps)40% Safety Data Safety Profile from Research What preclinical and early clinical studies report Preclinical Safety Summary LD50Not achieved Acute toxicityNone observed Chronic toxicityNone in 6-month studies Organ toxicityNone detected Human IV pilot (n=2)No adverse effects Cardiac/hepatic/renalNo effects detected Regulatory & Risk Considerations FDA statusUnapproved drug WADA statusBanned since 2022 (S0) Human trialsPhase 1 only Long-term effectsUnknown in humans Pro-angiogenic riskTheoretical unstudied Australia/NZPrescription only No lethal dose was reached in preclinical toxicology studies

It was also shown to improve inflammation and walking distances

NAC may also help combat drug-induced liver damage and heavy metal toxicity

Science Briefs The latest short science news items from C&EN